ESC Premium Access

Assessment of absolute reductions in LDL-C associated with alirocumab therapy: results from across the Phase 3 ODYSSEY programme

Topic: Lipids (Epidemiology and Prevention)

Congress Presentation

About the speaker

Doctor Eli Roth

University of Cincinnati, Cincinnati (United States of America)
0 follower

14 more presentations in this session

Open-label ODYSSEY APPRISE study: interim data from the first 843 participants

Speaker: Professor B. Cariou (Nantes, FR)


A one-year intervention combining weight loss and exercise increases the proportion of lipoprotein constituted by HDL and HDL particle size

Speaker: Doctor L. Pedersen (Copenhagen, DK)


Discordant low-density lipoprotein particle number versus low-density lipoprotein cholesterol is associated with increased C-reactive protein and poorer outcomes

Speaker: Doctor J. Meeusen (Rochester, US)


The cost-effectiveness of PCSK9 inihibitors in Australia

Speaker: Doctor E. Zomer (Melbourne, AU)


Coronary artery calcification is an independent predictor of cardiovascular events in familial hypercholesterolemia

Speaker: Associate Professor R. Santos (Sao Paulo, BR)


Access the full session

Poster session 2 - Lipids

Speakers: Doctor E. Roth, Professor B. Cariou, Doctor L. Pedersen, Doctor J. Meeusen, Doctor E. Zomer...

About the event


ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb